Summary
What is known and objective: Vaccines and other pharmaceuticals are essential medical supplies that require continuous storage at specific temperatures to maintain viability. Power outages can lead to a break in the cold chain, resulting in the degradation of essential medicines.
Comment:
After a power outage, the stability of vaccines and other medicines can be difficult to ascertain. Many public health guidelines therefore recommend discarding potentially compromised pharmaceuticals unless the cold chain can be guaranteed-a costly endeavour. There are government guidelines aimed at minimizing exposure to high temperatures in the event of a power outage; however, the usefulness of these guidelines is uncertain.
What is new and conclusion:
The actual cost of vaccine and pharmaceutical loss due to a break in the cold chain is poorly studied and requires further research. Additional recommendations regarding the stability of specific medicines would also be a valuable resource.
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cold-chain breach, medication stability, medication wastage, power outage, refrigerated medicines 738 | COMMENTARY CCB, due to the unpredictable nature of power outages and variability in drug degradation on exposure to increased temperatures. 4 There are some protocols and recommended procedures provided by manufacturers to determine the stability of drugs when a CCB has occurred.
However, stability research is generally limited, so many public health guidelines state that refrigerated pharmaceuticals should be discarded unless maintenance of the cold chain can be assured. 3 Contingency plans in the case of power outages are recommended by many governments and other organizations for the maintenance of vaccine efficacy. [5] [6] [7] [8] [9] Whereas there is some variation between specific recommendations, broadly speaking these plans recommend addressing (i) whether there is a backup power supply to the relevant refrigerators; (ii) whether a temperature-monitored refrigerator at an alternative site can be used, with an agreement in place to use the facility; (iii) if coolers are to be used, whether they are large enough to contain all the vaccine stocks; and (iv) whether ice/gel packs, insulating material (polystyrene/bubble wrap) and a minimum/maximum thermometer or data logger are available.
However, there is limited research indicating whether these contingency plans are effective and widely utilized. Furthermore, contingency plans are only viable if the temperature of the refrigerator or backup containers being used can be monitored for temperature range;
otherwise, CCB complications still arise. 10, 11 The use of purpose-built vaccine refrigerators has been recommended to maintain a stable temperature for vaccine storage, 5 and in some cases, they are the only refrigerators permitted for vaccine storage. 
| WHAT IS NE W AND CON CLUS I ON
The loss of vaccines and other pharmaceuticals due to CCB is likely to present a significant financial burden worldwide; however, the actual costs involved are poorly studied. Data from a small local study indicate millions of dollars worth of medicines could be saved each year if additional data regarding the stability of medicines were available to the relevant parties. Furthermore, whereas recommendations for dealing with power outages are provided by several sources, data from the study also revealed a lack of knowledge on the correct procedures to follow in such circumstances. Further research to examine the extent of this issue would aid in identifying the principal difficulties associated with CCB due to power outages and the accompanying costs; this would encourage investment in stability testing of specific products after CCB, along with the development and dissemination of more comprehensive and useful guidelines for health professionals.
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